Market revenue in 2023 | USD 13.7 million |
Market revenue in 2030 | USD 30.7 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 48.18% in 2023. Horizon Databook has segmented the Middle East & Africa peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In the Middle East and Africa region, the peanut allergy treatment market is marked by varying prevalence rates across different countries. Although the prevalence of peanut allergy is relatively low in some areas, there is a growing concern in several countries.
For instance, in Kuwait and Saudi Arabia, where peanut allergy prevalence rates are around 1.3% and 0.4%, respectively, the market presents opportunities for growth. There is a need for accessible and effective treatments, which could involve partnerships with global pharmaceutical companies and the development of locally tailored solutions.
In South Africa, the situation seems to be more reliant on traditional treatments, and access to advanced therapies might be limited. The focus should be on increasing awareness and promoting the importance of carrying injectable adrenaline, especially for individuals at risk of severe reactions.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account